Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

Related Keywords

New York ,United States ,California ,Houston ,Texas ,Poland ,Sant Chawla ,Jenene Thomas ,Walter Klemp ,Moleculin Biotech Inc ,Linkedin ,Twitter ,Drug Administration ,Cancer Center ,Nasdaq ,Sarcoma Oncology Center ,Company Us Phase ,Exchange Commission ,Securities Exchange ,Facebook ,Moleculin Biotech ,Cleveland Clinic ,Southern California ,Principal Investigator ,Annamycin Clinical ,Fast Track Status ,Orphan Drug Designation ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Pfizer Injectables ,Nc ,